Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aroa BiosurgeryASX:ARX -1.72%58 Equity-to-Asset is 0.82 as of Mar. 2026, which is 5% below its 10-year median of 0.86. GuruFocus rates ASX:ARX with a GF Score™ of 58/100 and a GF Value™ of A$0.83 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 851 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 78.38% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aroa Biosurgery's Total Stockholders Equity for the quarter that ended in Mar. 2026 was A$82.84 Mil. Aroa Biosurgery's Total Assets for the quarter that ended in Mar. 2026 was A$100.60 Mil.
Therefore, Aroa Biosurgery's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.82.
The historical rank and industry rank for Aroa Biosurgery's Equity-to-Asset or its related term are showing as below:
ASX:ARX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.86 Max: 0.89
Current: 0.82
During the past 7 years, the highest Equity to Asset Ratio of Aroa Biosurgery was 0.89. The lowest was 0.59. And the median was 0.86.
ASX:ARX's Equity-to-Asset is ranked better than 78.38% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ASX:ARX: 0.82
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aroa Biosurgery Equity-to-Asset Related Terms
Aroa Biosurgery Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ARX vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Aroa Biosurgery's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aroa Biosurgery's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a Equity-to-Asset of 0.82 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aroa Biosurgery and its competitors. This is near median its historical median of 0.86. Over the past decade, Aroa Biosurgery's Equity-to-Asset has ranged from 0.59 to 0.89. According to the industry distribution chart, Aroa Biosurgery ranks #184 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 21.6%.
Is Aroa Biosurgery's Equity-to-Asset too high?
Aroa Biosurgery's current Equity-to-Asset of 0.82 is near median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.89. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Aroa Biosurgery's value of 0.82 is 28.1% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #184 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #184 out of 851 companies for Equity-to-Asset. This places Aroa Biosurgery in the top 22% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Aroa Biosurgery's value of 0.82 is 28.1% above this benchmark. Historically, Aroa Biosurgery's own Equity-to-Asset has ranged from 0.59 to 0.89 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 0.64, Aroa Biosurgery has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current Equity-to-Asset of 0.82 is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.83, compared to a current price of A$0.57 — trading 31.3% below its estimated fair value. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.86 and 28.1% above the Medical Devices & Instruments industry median of 0.64. Aroa Biosurgery's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Equity-to-Asset is 0.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.57 is trading 31.3% below its estimated GF Value™ of A$0.83.
GuruFocus considers Aroa Biosurgery to be Significantly Undervalued.
Key valuation signals for ASX:ARX:
Equity-to-Asset: 0.82 (near median its 10-year median of 0.86)
GF Value™: A$0.83 vs. price of A$0.57 (31.3% below fair value)
Industry Position: 28.1% above the Medical Devices & Instruments median (#184 of 851)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
58GF Score
Get the complete analysis for ASX:ARX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
